BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 30337641)

  • 41. Repolarization of tumor infiltrating macrophages and increased survival in mouse primary CNS lymphomas after XPO1 and BTK inhibition.
    Jiménez I; Carabia J; Bobillo S; Palacio C; Abrisqueta P; Pagès C; Nieto JC; Castellví J; Martínez-Ricarte F; Escoda L; Perla C; Céspedes Torrez DH; Boix J; Purroy N; Puigdefàbregas L; Seoane J; Bosch F; Crespo M
    J Neurooncol; 2020 Aug; 149(1):13-25. PubMed ID: 32691208
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A novel Bcl-2 inhibitor, BM-1197, induces apoptosis in malignant lymphoma cells through the endogenous apoptotic pathway.
    Sun YL; Jiang WQ; Luo QY; Yang DJ; Cai YC; Huang HQ; Sun J
    BMC Cancer; 2019 Dec; 20(1):1. PubMed ID: 31892356
    [TBL] [Abstract][Full Text] [Related]  

  • 43. ELK4 neutralization sensitizes glioblastoma to apoptosis through downregulation of the anti-apoptotic protein Mcl-1.
    Day BW; Stringer BW; Spanevello MD; Charmsaz S; Jamieson PR; Ensbey KS; Carter JC; Cox JM; Ellis VJ; Brown CL; Walker DG; Inglis PL; Allan S; Reynolds BA; Lickliter JD; Boyd AW
    Neuro Oncol; 2011 Nov; 13(11):1202-12. PubMed ID: 21846680
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Targeting antioxidant enzymes enhances the therapeutic efficacy of the BCL-X
    Oh Y; Jung HR; Min S; Kang J; Jang D; Shin S; Kim J; Lee SE; Sung CO; Lee WS; Lee C; Jeong EM; Cho SY
    Cancer Lett; 2021 Jan; 497():123-136. PubMed ID: 33068701
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Anti-tumor activity of selective inhibitors of XPO1/CRM1-mediated nuclear export in diffuse malignant peritoneal mesothelioma: the role of survivin.
    De Cesare M; Cominetti D; Doldi V; Lopergolo A; Deraco M; Gandellini P; Friedlander S; Landesman Y; Kauffman MG; Shacham S; Pennati M; Zaffaroni N
    Oncotarget; 2015 May; 6(15):13119-32. PubMed ID: 25948791
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Bcl-xL inhibition - a novel strategy for glioma therapy.
    Karpel-Massler G; Siegelin MD
    Aging (Albany NY); 2016 Sep; 8(9):1830-1831. PubMed ID: 27687793
    [No Abstract]   [Full Text] [Related]  

  • 47. Selinexor (KPT-330) Induces Tumor Suppression through Nuclear Sequestration of IκB and Downregulation of Survivin.
    Nair JS; Musi E; Schwartz GK
    Clin Cancer Res; 2017 Aug; 23(15):4301-4311. PubMed ID: 28314790
    [No Abstract]   [Full Text] [Related]  

  • 48. ABT-199-mediated inhibition of Bcl-2 as a potential therapeutic strategy for nasopharyngeal carcinoma.
    Wang Y; Wang Y; Fan X; Song J; Wu H; Han J; Lu L; Weng X; Nie G
    Biochem Biophys Res Commun; 2018 Sep; 503(3):1214-1220. PubMed ID: 30017199
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Targeted BCL2 inhibition effectively inhibits neuroblastoma tumour growth.
    Lamers F; Schild L; den Hartog IJ; Ebus ME; Westerhout EM; Ora I; Koster J; Versteeg R; Caron HN; Molenaar JJ
    Eur J Cancer; 2012 Nov; 48(16):3093-103. PubMed ID: 22366560
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Specific inhibition of the nuclear exporter exportin-1 attenuates kidney cancer growth.
    Wettersten HI; Landesman Y; Friedlander S; Shacham S; Kauffman M; Weiss RH
    PLoS One; 2014; 9(12):e113867. PubMed ID: 25461627
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Identifying drug-target selectivity of small-molecule CRM1/XPO1 inhibitors by CRISPR/Cas9 genome editing.
    Neggers JE; Vercruysse T; Jacquemyn M; Vanstreels E; Baloglu E; Shacham S; Crochiere M; Landesman Y; Daelemans D
    Chem Biol; 2015 Jan; 22(1):107-16. PubMed ID: 25579209
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A novel therapeutic combination sequentially targeting aurora B and Bcl-xL in hepatocellular carcinoma.
    Matsunaga H; Tanaka S; Aihara A; Ogawa K; Matsumura S; Ban D; Ochiai T; Irie T; Kudo A; Nakamura N; Arii S; Tanabe M
    Ann Surg Oncol; 2015 Sep; 22(9):3079-86. PubMed ID: 25524010
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Simultaneous targeting of XPO1 and BCL2 as an effective treatment strategy for double-hit lymphoma.
    Liu Y; Azizian NG; Dou Y; Pham LV; Li Y
    J Hematol Oncol; 2019 Nov; 12(1):119. PubMed ID: 31752970
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Combinatorial targeting of XPO1 and FLT3 exerts synergistic anti-leukemia effects through induction of differentiation and apoptosis in
    Zhang W; Ly C; Ishizawa J; Mu H; Ruvolo V; Shacham S; Daver N; Andreeff M
    Haematologica; 2018 Oct; 103(10):1642-1653. PubMed ID: 29773601
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Induction of synthetic lethality in IDH1-mutated gliomas through inhibition of Bcl-xL.
    Karpel-Massler G; Ishida CT; Bianchetti E; Zhang Y; Shu C; Tsujiuchi T; Banu MA; Garcia F; Roth KA; Bruce JN; Canoll P; Siegelin MD
    Nat Commun; 2017 Oct; 8(1):1067. PubMed ID: 29057925
    [TBL] [Abstract][Full Text] [Related]  

  • 56. XPO1 blockade with KPT-330 promotes apoptosis in cutaneous T-cell lymphoma by activating the p53-p21 and p27 pathways.
    Chakravarti N; Boles A; Burzinski R; Sindaco P; Isabelle C; McConnell K; Mishra A; Porcu P
    Sci Rep; 2024 Apr; 14(1):9305. PubMed ID: 38653804
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Neutralization of BCL-2/X
    Zoeller JJ; Vagodny A; Taneja K; Tan BY; O'Brien N; Slamon DJ; Sampath D; Leverson JD; Bronson RT; Dillon DA; Brugge JS
    Mol Cancer Ther; 2019 Jun; 18(6):1115-1126. PubMed ID: 30962322
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical Implications of Targeting XPO1-mediated Nuclear Export in Multiple Myeloma.
    Gandhi UH; Senapedis W; Baloglu E; Unger TJ; Chari A; Vogl D; Cornell RF
    Clin Lymphoma Myeloma Leuk; 2018 May; 18(5):335-345. PubMed ID: 29610030
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The small-molecule compound BM-1197 inhibits the antiapoptotic regulators Bcl-2/Bcl-xL and triggers apoptotic cell death in human colorectal cancer cells.
    Ye L; Yuan G; Xu F; Sun Y; Chen Z; Chen M; Li T; Sun P; Li S; Sun J
    Tumour Biol; 2015 May; 36(5):3447-55. PubMed ID: 25542230
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Selinexor decreases HIF-1α via inhibition of CRM1 in human osteosarcoma and hepatoma cells associated with an increased radiosensitivity.
    von Fallois M; Kosyna FK; Mandl M; Landesman Y; Dunst J; Depping R
    J Cancer Res Clin Oncol; 2021 Jul; 147(7):2025-2033. PubMed ID: 33856525
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.